Molekyylikemian
Molekyylikemian is an Estonian biotechnology firm established in 2010 in Tallinn. The company concentrates on developing small‑molecule drugs for metabolic disorders. It specializes in synthetic organic chemistry, high‑throughput screening, and structure‑activity relationship studies. Its flagship pipeline agent is MK‑123, an orally bioavailable inhibitor targeting monoamine oxidase B, which is currently in phase II clinical trials. The company collaborates with the University of Tartu’s Department of Organic Chemistry and the Estonian Research Council.
Molekyylikemian employs approximately 70 scientists, including chemists, pharmacologists, and computational modelers. The corporate headquarters features a
Molekyylikemian has been recognized by the Estonian Ministry of Economic Affairs as a key innovator in the